Jagsonpal Pharmaceutical Ltd. announced that its board of directors will meet on Thursday, March 12, 2026, to consider and approve a buyback proposal for fully-paid up equity shares with a face value of ₹2 each. According to reports from CNBC TV18 and The Economic Times, this marks the first instance that the company will approve a share buyback proposal if it proceeds with the plan. The board meeting was formally announced to the exchanges on Monday, March 10, 2026, with the company informing the Bombay Stock Exchange (BSE) about the upcoming consideration.
The pharmaceutical company has a history of corporate actions, including a 3:1 bonus share issue in July 2004, where shareholders received three free shares for every one share held as on the record date. As reported by CNBC TV18 and The Economic Times, the company also conducted a stock split in January 2025, dividing shares with a face value of ₹5 into shares of ₹2 each. These previous actions demonstrate the company's pattern of enhancing shareholder value through various corporate mechanisms.
Jagsonpal Pharma has maintained a consistent dividend payment schedule, declaring a final dividend of ₹2.5 in September 2025. According to CNBC TV18 and The Economic Times, the company had previously declared dividends of ₹5 in September 2024 and August 2023, respectively. In 2021, the company declared two dividends of ₹4 and ₹1 in October and September. The latest dividend declaration in September 2025 represents the company's most recent shareholder return initiative.
Shares of Jagsonpal Pharmaceutical closed 2.5% lower at ₹169.05 in the previous trading session, as reported by CNBC TV18 and The Economic Times. The stock has experienced significant declines, falling 8.4% in the past month, 31% in the last six months, and 12.2% year-to-date. The current share price reflects the market's response to the company's upcoming board meeting and potential share buyback announcement.
